Emvena Therapeutics Secures First Investment From $50 Million Penn-BioNTech Fund To Advance Placenta-Targeted mRNA Medicines
· pulse2.com · popularity 19/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at pulse2.com →
Summary
Emvena Therapeutics, a Philadelphia-based biotechnology company developing placenta-targeted messenger RNA medicines, has received the inaugural investment from the Penn-BioNTech Innovative Therapeutics Seed Fund. The financing will support development of Emvena's investigational treatment platform for serious maternal and fetal conditions, beginning with preeclampsia. The post Emvena Therapeutics Secures First Investment From $50 Million Penn-BioNTech Fund To Advance Placenta-Targeted mRNA Medicines appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 7.